Establishment and Discussion of the Drug Utility Related Risk Causal Model

Abstract

Abstract: Objective To establish and discuss the drug utility related risk causal model. Methods The works concerning the foundation of this article, namely risk theory and pharmacotherapeutics, were summarized and analyzed. Results & Conclusion Hazard, loss, peril were the three key elements of risk, they constituted the causal model together with contributory and intercept factors, which took important role in complex system. In the view of causal model, the drug characters were the hazard, which contributed most drug related peril and loss. The contributory factors included the healthcare staff's clinical decision and related implementation, as well as the condition of the patients. The regulation, SOPs and individual experience, perception and communication were acted as intercept factors. The casual model would give rise to the acknowledgement of the drug related risk source, process, which would enhance drug utility management.

Key words: drug, clinical use, risk

CLC Number:

R954

LI Chun-xiao, WU Zhi-ang ,HU Xin. Establishment and Discussion of the Drug Utility Related Risk Causal Model [J]. Chinese Journal of Pharmacovigilance, 2013, 10(9): 549-552.

References

[1] Van Boxtel C J, Santoso B, Edwards I R. Drug benefits and risks: international textbook of clinical pharmacology [M]. Amsterdam: IOS Press, 2008:6.
[2] Uhl K, Trontell A, Kennedy D. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools[J]. Pharmacoepidemiology And Drug Safety, 2007, 16(3): 337-348.
[3] CastanedaC P, ZeldisJ B, Freeman J, et al. RevAssist[J]. Drug Safety, 2008, 31(9): 743-752.
[4] 吴波.隧道施工安全风险管理研究与实务[M].北京:中国铁道出版社, 2010: 9-12.
[5]艾孙麟.保险学原理[M].武汉:武汉大学出版社, 2007:4.
[6] Carroll J S. Incident reviews in high-hazard industries: sense making and learning under ambiguity and accountability [J].Organization & Environment, 1995, 9(2): 175-197.
[7] La PorteT R, Rochlin G. A rejoinder to Perrow[J]. Journal of Contingencies and Crisis Management, 1994, 2(4): 221-227.
[8] Manley M T. Incidence, contributory factors and costs of pressure sores[J].South African Medical Journal, 1978, 53(6): 217-222.
[9] Vincent C, Taylor A S, ChapmanE J, et al. How to investigate and analyse clinical incidents: clinical risk unit and association of litigation
and risk management protocol [J]. British Medical Journal, 2000, 320(7237): 777-781.
[10] Tighe C M, Woloshynowych M, Brown R, et al. Incident reporting in one UK accident and emergency department [J ] . Accident And Emergency Nursing, 2006, 14(1): 27-37.
[11] Vincent C, TaylorA S, ChapmanE J, et al. How to investigate and analyse clinical incidents: clinical risk unit and association of litigation and risk management protocol[J]. British Medical Journal, 2000, 320(7237): 777.
[12] Reason J. Human error: models and management[J]. British Medical Journal, 2000, 320(7237): 768.
[13] BrennanT A, Leape L L, Laird N M, et al. Incidence of adverse events and negligence in hospitalized patients. Negligence And The Best Practice Model [ J ] . New England Journal of Medicine, 1991, 324(6): 370-376.
[14]陈玉和.风险评价[D].北京:中国标准出版社,2009: 20-27.
[15]李庆功.临床风险管理[M].北京:人民卫生出版社, 2009: 35-40.
[16] Van Boxtel C J, Santoso B, Edwards I R. Drug benefits and risks: international textbook of clinical pharmacology [M]. Amsterdam: IOS Press, 2008:95-145.
[17]温伟,纪立伟,张新超.胺碘酮静脉滴注致急性肝损害15例临
床分析[J].药物不良反应杂志, 2006, 8(2): 105-109.
[18]张岁龙,叶莎.静脉注射胺碘酮治疗快速室上性心律失常60例临床观察[J]. 陕西医学杂志, 2010 (005): 579-581.
[19] Zhou S F, Zhou Z W, Yang L P, et al. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development[J].CurrentMedicinal Chemistry, 2009, 16(27): 3480-3675.
[20] 李庆功.临床风险管理[M].北京:人民卫生出版社, 2009:19-28.
[21] Bates D W, Cullen D J, Laird N, et al. Incidence of adverse drug events and potential adverse drug events[J]. Journal of the American medical association, 1995, 274(1): 29-34.
[22] ISO. Risk management - Principles and guidelines on implementation[S]. Geneva: ISO/DIS 31000, 2009:3-14.
[23] Thomas E J, Studdert D M, Burstin H R, et al. Incidence and types of adverse events and negligent care in Utah and Colorado[J].Medical Care, 2000, 38(3): 261-271.
[24] Leape LL. Error in medicine [J]. Journal Of The American Medical Association, 1994, 272:1851-1858.
[25] Woodward S. Seven steps to patient safety[J]. Revista de Calidad Asistencial, 2005, 20(2): 66-70.